Roche, Novartis slam Italian cartel fine
This article was originally published in Scrip
Roche and Novartis have reacted angrily to a decision by the Italian Competition Authority to fine them €182.5m for what it described as "illicit collusion" to exclude Roche's Avastin from the ophthalmology market in favor of Novartis's similar drug Lucentis.
You may also be interested in...
In the latest in a string of knockbacks for both Novartis and Roche, the EU’s highest court has said that the Italian authorities are within their rights to reimburse Roche’s Avastin for wet AMD, even though it is not approved for that indication.
In the latest development in the long-running case pitting Novartis and Roche against the Italian competition authority over a fine imposed in 2014, the Court of Justice of the EU has confirmed that the firms’ arrangement over Avastin and Lucentis could constitute a serious restriction on competition if it involved the dissemination of misleading information. The case now goes back to the Italian court.
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.